Drug intelligence / Profile preview

LU AA34893

Development stage: Discontinued
Lead developer: Lundbeck
Modality: Small Molecules
Administration: Oral

Overview

LU AA34893 is an investigational small molecule antidepressant developed by Lundbeck for the oral treatment of major depressive disorder and bipolar depression. It acts as a serotonin receptor modulator, affecting several monoaminergic systems with allosteric effects. Preclinical studies suggested superior antidepressant efficacy compared to existing treatments, but clinical development was discontinued after Phase 2 trials for both major depressive disorder and bipolar disorders[1][2][3][6].

Targets

5-HT (Serotonin receptors)

Beyond the preview

Go deeper on LU AA34893.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LU AA34893.

Explore the full profile